Skip to main content

Profiles

Brighton Collaboration

The Brighton Collaboration Foundation, or simply the Brighton Collaboration, is a non-governmental organization based in Basel, Switzerland. It is a program under the Task Force for Global Health which provides administration services and support, including the management of all of the Collaboration’s donations and grants.

History

The Brighton Collaboration originated in 1999 and formed in 2000 to define safety parameters for vaccines, then collect and disseminate it to encourage vaccine uptake worldwide.[1]

In May 2019, Brighton and the Coalition for Epidemic Preparedness Innovations (CEPI) partnered to launch the Safety Platform for Emergency vACcines (SPEAC).[2]

COVID-19

In June 2020, Brighton published a report titled “Priority List of Adverse Events of Special Interest: COVID-19.”[3] It was updated several times up to December 2020. The report was commissioned by CEPI.

Redefining anaphylaxis

The Brighton Collaboration convened an "anaphylaxis working group" in June 2021 consisting of ten members in order to update and revise the definition of anaphylaxis.[4]

Organization

The Brighton Collaboration is a program of the Task Force for Global Health. Currently, the primary funding for the Brighton Collaboration comes from the Coalition for Epidemic Preparedness Innovations (CEPI).

It is a member of the World Health Organization's Vaccine Safety Net, is partnered with the Vaccine Confidence Project,[5] and is associated with HELP Eliminate Pain in Kids & Adults.[6]

Personnel

Name Position Notes
Ananda Amarasinghe Anaphylaxis Working Group member[4:1] WHO Regional Office for the Western Pacific
Michael Gold Anaphylaxis Working Group member University of Adelaide Medical School
Matthew Greenhawt Anaphylaxis Working Group member Children's Hospital Colorado, University of Colorado School of Medicine
John Kelso Anaphylaxis Working Group member Scripps Clinic
Sonali Kochhar Anaphylaxis Working Group member University of Washington Department of Global Health
Bernard Yu-Hor Thong Anaphylaxis Working Group member Tan Tock Seng Hospital
Karina Top Anaphylaxis Working Group member Vaccine Surveillance Reference Group (VSRG), Dalhousie University
Paul Turner Anaphylaxis Working Group member National Heart and Lung Institute, University of Sydney
Margitta Worm Anaphylaxis Working Group member Charité – Berlin University Medicine

Activities

The Brighton Collaboration has provided funding to the World Health Organization.[7]

Publications

Priority List of Adverse Events of Special Interest: COVID-19

Further reading

  1. About. Brighton Collaboration. Retrieved April 19, 2022, from https://web.archive.org/web/20220419230552/https://brightoncollaboration.us/about/ ↩︎

  2. Safety Platform for Emergency vACcines (SPEAC). (2019, May 9). Brighton Collaboration. https://web.archive.org/web/20221130041630/https://brightoncollaboration.us/cepi-partners-with-brighton-collaboration-to-support-safety-assessment-of-vaccine-candidates/ ↩︎

  3. Priority List of Adverse Events of Special Interest: COVID-19. (2020, June 10). Brighton Collaboration. http://archive.today/2021.07.15-031510/https://brightoncollaboration.us/priority-list-aesi-covid/ ↩︎

  4. Gold, M. S., Amarasinghe, A., Greenhawt, M., Kelso, J. M., Kochhar, S., Yu-Hor Thong, B., Top, K. A., Turner, P. J., Worm, M., & Law, B. (2022). Anaphylaxis: Revision of the Brighton collaboration case definition. Vaccine, 41(15). https://doi.org/10.1016/j.vaccine.2022.11.027 ↩︎ ↩︎

  5. Partners & Funders. Vaccine Confidence Project. Retrieved April 28, 2022, from https://web.archive.org/web/20220428122506/https://www.vaccineconfidence.org/partners-funders ↩︎

  6. Organizations & Groups (utilizing our work). HELPinKids&Adults. Retrieved February 24, 2024, from https://web.archive.org/web/20240224194827/https://phm.utoronto.ca/helpinkids/publications3.html ↩︎

  7. Voluntary contributions by fund and by contributor, 2017. (2018, April 19). World Health Organization. https://web.archive.org/web/20200605174758/https://www.who.int/about/finances-accountability/funding/A71_INF2-en.pdf ↩︎